Article

<i>TP53</i> Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia

2025-03-27

Abstract excerpt

<h4>ABSTRACT</h4> Acute myeloid leukemia (AML) is a heterogeneous cancer that is associated with poor outcomes. Revumenib and other menin inhibitors have shown promising activity against AMLs with KMT2A -rearrangements or NPM1 mutations. However, mechanisms of de novo resistance have not yet been elucidated. We analyzed a panel of cell lines and generated an isogenic model to assess the impact of TP53 mutatio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fd4e9cd2-1f26-558f-a0da-0b77514ee349
DOI: 10.1101/2025.03.24.644993

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>TP53</i> Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid LeukemiaDOI 10.1101/2025.03.24.644993Read

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaSemantic proximity Read

What have we learned about TP53-mutated acute myeloid leukemia?Semantic proximity Read

Revumenib for patients with acute leukemia: a new tool for differentiation therapySemantic proximity Read

Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatmentsSemantic proximity Read

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.Semantic proximity Read

<i>TP53</i> mutations drive therapy resistance via post-mitochondrial caspase blockadeSemantic proximity Read

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclaxSemantic proximity Read

Combination Strategies with Menin Inhibitors for Acute LeukemiaSemantic proximity Read

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.Semantic proximity Read

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical DevelopmentsSemantic proximity Read

<i>TP53</i> mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistanceSemantic proximity Read

Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia.Semantic proximity Read